[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

MX9710261A - Compuestos aromaticos y composiciones farmaceuticas que los contienen. - Google Patents

Compuestos aromaticos y composiciones farmaceuticas que los contienen.

Info

Publication number
MX9710261A
MX9710261A MX9710261A MX9710261A MX9710261A MX 9710261 A MX9710261 A MX 9710261A MX 9710261 A MX9710261 A MX 9710261A MX 9710261 A MX9710261 A MX 9710261A MX 9710261 A MX9710261 A MX 9710261A
Authority
MX
Mexico
Prior art keywords
hydroxybenzylamino
optionally substituted
benzoic acid
dihydroxybenzylamino
ring
Prior art date
Application number
MX9710261A
Other languages
English (en)
Inventor
Gloria Anne Breault
Original Assignee
Zeneca Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9512475.6A external-priority patent/GB9512475D0/en
Priority claimed from GBGB9601465.9A external-priority patent/GB9601465D0/en
Application filed by Zeneca Ltd filed Critical Zeneca Ltd
Publication of MX9710261A publication Critical patent/MX9710261A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/79—Acids; Esters
    • C07D213/80—Acids; Esters in position 3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/455—Nicotinic acids, e.g. niacin; Derivatives thereof, e.g. esters, amides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/81—Amides; Imides
    • C07D213/82—Amides; Imides in position 3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
    • C07D237/02—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings
    • C07D237/06—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D237/10—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D237/18—Sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
    • C07D237/02—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings
    • C07D237/06—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D237/10—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D237/24—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pain & Pain Management (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Rheumatology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pyridine Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicinal Preparation (AREA)
  • Hydrogenated Pyridines (AREA)

Abstract

La invencion se relaciona con compuestos de la formula (I), en el que A es un sistema en el anillo opcionalmente sustituido, con la condicion de que los grupos -CH(r3)N(R2)B-R1 y -OD sean colocados en una relacion 1,2 a diferentesátomos de carbono en el anillo y el átomo en el anillo colocado de orto al grupo de enlace -OD (y por lo tanto en la posicion 3 con relacion al grupo de enlace -CHR3NR2-) no sean sustituidos; B es un sistema de anillo opcionalmente sustituido; R1 está colocado en el anillo B en una relacion 1,3 o 1,4 con el grupo de enlace -CH(R3)N(R2)- y es como se definio en la descripcion; R2 es hidrogeno, alquilo de C1-6, opcionalmente sustituido por hidroxi, ciano o trifluorometilo, alquenilo de C2-6 (no se proporciona el enlace doble en la posicion 1), alquinilo de C2-6 (no se proporciona el enlace tripe en la posicion 1), fenil-alquilo de C1-3 o piridil-alquilo de C1-3; R3 es hidrogeno, metilo o etilo; D es hidrogeno, un anillo carbocíclico opcionalmente sustituido con 5-7 miembros que contienen un doble enlace, alquilo de C1-3 sustituido por un anillo carbocíclico opcionalmente sustituido con 5-7 miembros que contiene un doble enlace o D es de la formula -(CH2)nCH(R4)C(R5)=C(R6)R7, y los N-oxidos de NR2 donde son químicamente posibles; y los S-oxidos de azufre que contienen los anillos, donde químicamente son posibles; y sus sales y ésteres hidrolizables in vivo y amidas farmacéuticamente aceptables excluyendo el ácido 4-[5-carboxi-2-hidroxibencilamino]-benzoico, el ácido 4-[2,5-dihidroxibencilamino]benzoico, el ácido 5-[2-hidroxibencilamino]-2-hidroxibenzoico, el ácido 3-[2,5-dihidroxibencilamino]benzoico, la 4-[2,5-dihidroxibencilamino]bencencarboxamida, el ácido 3-[2-hidroxibencilamino]benzoico, el ácido 4-[2,5-dihidroxibencilamino]-2-hidroxibenzoico, el ácido 4-[2-hidroxibencilamino]-2-hidroxibenzoico y el ácido 4-[2-hidroxibencilamino]benzoico. Procesos para su preparacion, intermediarios en su preparacion, su uso como agentes terapéuticos y composiciones farmacéuticas que los contienen.
MX9710261A 1995-06-20 1996-06-17 Compuestos aromaticos y composiciones farmaceuticas que los contienen. MX9710261A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB9512475.6A GB9512475D0 (en) 1995-06-20 1995-06-20 Aromatic compounds
GBGB9601465.9A GB9601465D0 (en) 1996-01-25 1996-01-25 Aromatic compounds
PCT/GB1996/001443 WO1997000864A1 (en) 1995-06-20 1996-06-17 Aromatic compounds and pharmaceutical compositions containing them

Publications (1)

Publication Number Publication Date
MX9710261A true MX9710261A (es) 1998-03-29

Family

ID=26307242

Family Applications (1)

Application Number Title Priority Date Filing Date
MX9710261A MX9710261A (es) 1995-06-20 1996-06-17 Compuestos aromaticos y composiciones farmaceuticas que los contienen.

Country Status (29)

Country Link
US (2) US6100258A (es)
EP (1) EP0847391B1 (es)
JP (1) JP3949167B2 (es)
KR (1) KR19990023007A (es)
CN (1) CN1114598C (es)
AR (1) AR004670A1 (es)
AT (1) ATE211132T1 (es)
AU (1) AU699691B2 (es)
BG (1) BG63778B1 (es)
BR (1) BR9608908A (es)
CA (1) CA2220529A1 (es)
CZ (1) CZ290924B6 (es)
DE (1) DE69618210T2 (es)
DK (1) DK0847391T3 (es)
EE (1) EE9700342A (es)
ES (1) ES2169248T3 (es)
HR (1) HRP960289B1 (es)
HU (1) HUP9802705A3 (es)
IL (1) IL118663A (es)
MX (1) MX9710261A (es)
MY (1) MY132432A (es)
NO (1) NO311131B1 (es)
NZ (1) NZ311083A (es)
PL (1) PL324166A1 (es)
PT (1) PT847391E (es)
RU (1) RU2198878C2 (es)
SK (1) SK282458B6 (es)
TW (1) TW502026B (es)
WO (1) WO1997000864A1 (es)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9514160D0 (en) * 1994-07-25 1995-09-13 Zeneca Ltd Aromatic compounds
GB9417532D0 (en) * 1994-08-31 1994-10-19 Zeneca Ltd Aromatic compounds
TW502026B (en) 1995-06-20 2002-09-11 Zeneca Ltd Aromatic compounds useful as antagonists of e-type prostaglandins, processes for the preparation thereof, pharmaceutical compositions comprising the compounds, and intermediates
TW434240B (en) 1995-06-20 2001-05-16 Zeneca Ltd Aromatic compounds, preparation thereof and pharmaceutical composition comprising same
EP0752421B1 (en) * 1995-07-07 2005-10-12 AstraZeneca AB Ortho-substituted aromatic compounds, containing three (het)aryl moieties, their preparation and their use as prostaglandin E2-(PGE2)-antagonists
ATE400653T1 (de) * 1995-07-26 2008-07-15 Astrazeneca Ab Chimäre rezeptoren und verfahren zur identifizieren verbindungen mit einem aktivität als metabotropischen glutamatrezeptoren sowie verwendung solcher verbindungen in der behandlung von neurologischer erkrankungen und neurologischenstörrungen
DE69826286T2 (de) 1997-06-27 2005-11-24 Fujisawa Pharmaceutical Co., Ltd. Derivate mit einem aromatischen ring
GB9903476D0 (en) 1999-02-17 1999-04-07 Zeneca Ltd Therapeutic agents
CN100374416C (zh) * 2000-04-28 2008-03-12 霍夫曼-拉罗奇有限公司 对(磺酰基)芳基和杂芳基类化合物
SE0100873D0 (sv) * 2001-03-13 2001-03-13 Astrazeneca Ab Method of treatment
ATE391503T1 (de) 2001-10-23 2008-04-15 Serono Lab Pyrazolidinon-verbindungen als liganden des ep2 und/oder ep4 prostaglandin-rezeptoren
WO2003053923A2 (en) 2001-12-20 2003-07-03 Applied Research Systems Ars Holding N.V. Pyrrolidine derivatives as prostaglandin modulators
CA2483555A1 (en) 2002-06-10 2003-12-18 Applied Research Systems Ars Holding N.V. Gamma lactams as prostaglandin agonists and use thereof
JP2006501247A (ja) * 2002-08-30 2006-01-12 バイオストラタム，インコーポレイティド ポストａｍａｄｒｉの後生的糖化最終産物の阻害物質
ATE455760T1 (de) 2004-12-06 2010-02-15 Merck Serono Sa Pyrrolidin-2-on-derivate zur verwendung als dp1- rezeptoragonisten
BRPI0519398A2 (pt) 2004-12-23 2009-01-20 Glaxo Group Ltd compostos de piridina para o tratamento de doenÇas mediadas por prostaglandina
US7767710B2 (en) * 2005-05-25 2010-08-03 Calosyn Pharma, Inc. Method for treating osteoarthritis
US20060269579A1 (en) * 2005-05-25 2006-11-30 Musculoskeletal Research Llc Compositions for treating osteoarthritis
NZ578988A (en) 2007-02-16 2012-03-30 Ono Pharmaceutical Co Therapeutic agent for urinary excretion disorder
WO2009042854A1 (en) * 2007-09-26 2009-04-02 Musculoskeletal Research Llc Ion-channel regulator compositions and methods of using same
WO2011133920A1 (en) 2010-04-23 2011-10-27 Cytokinetics, Inc. Certain amino-pyridines and amino-triazines, compositions thereof, and methods for their use
AR081626A1 (es) 2010-04-23 2012-10-10 Cytokinetics Inc Compuestos amino-piridazinicos, composiciones farmaceuticas que los contienen y uso de los mismos para tratar trastornos musculares cardiacos y esqueleticos
AR081331A1 (es) 2010-04-23 2012-08-08 Cytokinetics Inc Amino- pirimidinas composiciones de las mismas y metodos para el uso de los mismos
US20120101282A1 (en) 2010-10-22 2012-04-26 Pascal Dott Process for the preparation of nicotinamide derivatives
US8759380B2 (en) 2011-04-22 2014-06-24 Cytokinetics, Inc. Certain heterocycles, compositions thereof, and methods for their use
PT3083554T (pt) * 2013-12-17 2019-06-11 Lilly Co Eli Compostos de ácido dimetilbenzóico

Family Cites Families (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3657430A (en) * 1969-06-25 1972-04-18 Merck & Co Inc Composition and methods for treating inflammation
US3632760A (en) * 1969-06-25 1972-01-04 Merck & Co Inc Treatment of inflammation
DE2120091A1 (de) * 1971-04-24 1972-11-09 Agfa-Gevaert Ag, 5090 Leverkusen Farbbildner für das Peroxid-Farbverstärkungs-Verfahren
US4350822A (en) * 1975-03-12 1982-09-21 American Cyanamid Company Antilipidemicpara-[aryl(alkyl or alkenyl)amino]benzoic acid derivatives
AU510758B2 (en) * 1976-01-19 1980-07-10 The Dow Chemical Company P-benzylaminobenzoic acids
US4206145A (en) * 1976-02-11 1980-06-03 Beecham Group Limited Hypolipidaemic compounds and compositions
GB1576007A (en) * 1976-02-11 1980-10-01 Beecham Group Ltd Hypolipidaemic compositions
EP0000816A1 (en) * 1977-08-06 1979-02-21 Beecham Group Plc Substituted amino-pyridine derivatives, processes for their preparation and pharmaceutical compositions containing them
US4152452A (en) * 1977-10-06 1979-05-01 William H. Rorer, Inc. Method of topically treating inflammation
GB2041363B (en) * 1979-01-19 1982-10-06 Pfizer Ltd N-benzyl-imidazoles
US4277496A (en) * 1979-06-04 1981-07-07 Laboratorios Bago S.A. Methods of treating mammals suffering from inflammation and pain
US4578390A (en) * 1981-12-14 1986-03-25 Merck & Co., Inc. Hydroxybenzylamino derivatives as anti-inflammatory agents
CA1193598A (en) * 1982-05-06 1985-09-17 Rafael Foguet 2-amino-benzoic acid derivatives and processes for their production
US5105017A (en) * 1983-07-18 1992-04-14 Eli Lilly And Company Leukotriene antagonist intermediates
GB8320699D0 (en) * 1983-08-01 1983-09-01 Wellcome Found Ethylenediamines
US4614617A (en) * 1985-02-25 1986-09-30 G. D. Searle & Co. Intermediates for 8-chlorodibenz[(b,f)][1,4]oxazepine-10(11H)-carboxylic acid, 2-(sulfinyl- and sulfonyl-containing acyl)hydrazides
US4725619A (en) * 1985-04-16 1988-02-16 Usv Pharmaceutical Corporation Aryl and heteroaryl ethers as agents for the treatment of hypersensitive ailments
US4631287A (en) * 1985-04-16 1986-12-23 Usv Pharmaceutical Corp. Aryl and heteroaryl ethers as agents for the treatment of hypersensitive ailments
US4839369A (en) * 1985-04-16 1989-06-13 Rorer Pharmaceutical Corporation Aryl and heteroaryl ethers as agents for the treatment of hypersensitive ailments
US4728668A (en) * 1985-04-16 1988-03-01 Usv Pharmaceutical Corporation Aryl and heteroaryl ethers as agents for the treatment of hypersensitive ailments
US4704386A (en) * 1985-08-29 1987-11-03 G. D. Searle & Co. 8-chlorodibenz[b,f][1,4]oxazepine-10(11H)-carboxylic acid, 2-[(phenylsulfinyl-, and phenylsulfonyl)alkanoyl]hydrazides
US4937373A (en) * 1988-12-08 1990-06-26 Hoffmann-La Roche Inc. Substituted naphthalene carboxylic acids
DE3903989A1 (de) * 1989-02-10 1990-09-20 Basf Ag Diphenylheteroalkylderivate, ihre herstellung und daraus hergestellte arzneimittel und kosmetika
US5210206A (en) * 1990-09-10 1993-05-11 Abbott Laboratories 1,3-oxazolyl substituted biphenyl
US5284954A (en) * 1990-09-10 1994-02-08 Abbott Laboratories Process for the preparation of tetrazoles
US5250548A (en) * 1990-09-10 1993-10-05 Abbott Laboratories Angiotensin II receptor antagonists
IL99246A0 (en) * 1990-09-10 1992-07-15 Abbott Lab Angiotensin ii receptor antagonists and pharmaceutical compositions containing them
GB9021813D0 (en) * 1990-10-08 1990-11-21 Ici Plc Tricyclic heterocycles
US5480883A (en) * 1991-05-10 1996-01-02 Rhone-Poulenc Rorer Pharmaceuticals Inc. Bis mono- and bicyclic aryl and heteroaryl compounds which inhibit EGF and/or PDGF receptor tyrosine kinase
SG64322A1 (en) * 1991-05-10 1999-04-27 Rhone Poulenc Rorer Int Bis mono and bicyclic aryl and heteroaryl compounds which inhibit egf and/or pdgf receptor tyrosine kinase
GB9120640D0 (en) * 1991-09-27 1991-11-06 Ici Plc Tricyclic heterocycles
DE4241632A1 (de) * 1992-12-10 1994-06-16 Thomae Gmbh Dr K Carbonsäurederivate, diese Verbindungen enthaltende Arzneimittel und Verfahren zu ihrer Herstellung
US5324743A (en) * 1992-12-10 1994-06-28 Eli Lilly And Company Leukotriene B4 antagonists
US5420270A (en) * 1993-10-07 1995-05-30 G. D. Searle & Co. Aryl substituted dibenzoxazepine compounds, pharmaceutical compositions and methods of use
US5441950A (en) * 1994-06-09 1995-08-15 G. D. Searle & Co. Substituted dibenzoxazepine and dibenzthiazepine carbamate compounds, pharmaceutical compositions and methods of use
GB9514160D0 (en) * 1994-07-25 1995-09-13 Zeneca Ltd Aromatic compounds
GB9417532D0 (en) * 1994-08-31 1994-10-19 Zeneca Ltd Aromatic compounds
GB9420557D0 (en) * 1994-10-12 1994-11-30 Zeneca Ltd Aromatic compounds
US5530157A (en) * 1995-02-16 1996-06-25 Scios Nova Inc. Anti-inflammatory benzoic acid derivatives
TW434240B (en) * 1995-06-20 2001-05-16 Zeneca Ltd Aromatic compounds, preparation thereof and pharmaceutical composition comprising same
TW502026B (en) * 1995-06-20 2002-09-11 Zeneca Ltd Aromatic compounds useful as antagonists of e-type prostaglandins, processes for the preparation thereof, pharmaceutical compositions comprising the compounds, and intermediates
EP0752421B1 (en) * 1995-07-07 2005-10-12 AstraZeneca AB Ortho-substituted aromatic compounds, containing three (het)aryl moieties, their preparation and their use as prostaglandin E2-(PGE2)-antagonists

Also Published As

Publication number Publication date
KR19990023007A (ko) 1999-03-25
RU2198878C2 (ru) 2003-02-20
MY132432A (en) 2007-10-31
CZ290924B6 (cs) 2002-11-13
AR004670A1 (es) 1999-03-10
WO1997000864A1 (en) 1997-01-09
US6313148B1 (en) 2001-11-06
NO311131B1 (no) 2001-10-15
ES2169248T3 (es) 2002-07-01
CN1114598C (zh) 2003-07-16
HRP960289B1 (en) 2002-10-31
TW502026B (en) 2002-09-11
BR9608908A (pt) 1999-03-02
EE9700342A (et) 1998-06-15
HRP960289A2 (en) 1997-12-31
NZ311083A (en) 2000-01-28
IL118663A (en) 2001-04-30
NO975984L (no) 1997-12-19
SK173397A3 (en) 1998-07-08
AU6232196A (en) 1997-01-22
EP0847391A1 (en) 1998-06-17
HUP9802705A2 (hu) 1999-02-01
SK282458B6 (sk) 2002-02-05
ATE211132T1 (de) 2002-01-15
EP0847391B1 (en) 2001-12-19
HUP9802705A3 (en) 1999-03-29
DK0847391T3 (da) 2002-03-25
CN1193966A (zh) 1998-09-23
PT847391E (pt) 2002-06-28
CA2220529A1 (en) 1997-01-09
AU699691B2 (en) 1998-12-10
BG102174A (en) 1998-09-30
NO975984D0 (no) 1997-12-19
JPH11507939A (ja) 1999-07-13
DE69618210T2 (de) 2002-07-18
CZ411097A3 (cs) 1998-03-18
PL324166A1 (en) 1998-05-11
US6100258A (en) 2000-08-08
BG63778B1 (bg) 2002-12-29
JP3949167B2 (ja) 2007-07-25
IL118663A0 (en) 1996-10-31
DE69618210D1 (de) 2002-01-31

Similar Documents

Publication Publication Date Title
MX9710261A (es) Compuestos aromaticos y composiciones farmaceuticas que los contienen.
MX9710218A (es) Compuestos aromaticos y composiciones farmaceuticas que los contienen.
MX9606541A (es) Aminoeteres aromaticos como agentes para aliviar el dolor.
OA09482A (fr) "Nouveaux dérivés à structure naphtalénique, leur procédé de préparation et les compositions pharmaceutiques qui les contiennent".
ATE141277T1 (de) Neue phosphonobernsteinsäurederivate, verfahren zu deren herstellung und diese verbindungen enthaltende arzneimittel
ATE83773T1 (de) 3(2h)pyridazinon, verfahren zu dessen herstellung und dieses enthaltendes mittel gegen srs-a.
ES8200011A1 (es) Procedimiento de preparacion de una composicion farmaceuticaen particular psicotropa.
BR8200949A (pt) Imidazodiazepinas,substancias farmaceutica ativas,processo para a fabricacao de compostos,medicamentos,medicamento esquistossomicidamente ativo e uso de compostos
DE68917220D1 (de) Phenylpyridon-Derivate, Verfahren zu ihrer Herstellung und diese enthaltende pharmazeutische Zusammensetzungen.
HUP0102025A2 (hu) Diaril-1,3,4-oxadiazolon-származékok, ezeket tartalmazó gyógyszerkészítmények és alkalmazásuk
FI104071B1 (fi) Analogiamenetelmä terapeuttisesti käyttökelpoisten 2,5-dihydro-2,5-diokso-1H-bents[b]atsepiinijohdannaisten valmistamiseksi
ATE149165T1 (de) Stickstoff enthaltende bizyklische derivate, verfahren zu ihrer herstellung und diese enthaltende pharmazeutische zubereitungen
IE832680L (en) Nitrosourea derivatives.
DK526087D0 (da) Antikonvulsive aminosyrederivater
DE3878967D1 (de) 17-aza-20,21-dinoreburnameninderivate, verfahren und zwischenprodukte zu ihrer herstellung, ihre anwendung als arzneimittel und diese enthaltende zubereitungen.
DE69409734D1 (de) Neue Derivate des 2-(1H)-Chinolinones, Verfahren zu ihrer Herstellung und sie enthaltende Arzneimittel
GR3020292T3 (en) Use of 2-iminothiazolidin-4-one derivatives as new medicaments
ES8707951A1 (es) Derivados de tetrazol
HUP9900079A2 (hu) 12H-Dibenzo[d,g][1,3]dioxocin-származékok, eljárás előállításukra, alkalmazásuk és az ezeket tartalmazó gyógyszerkészítmények
ATE43594T1 (de) 3-alkoxy-2-(n-pyrrolidino)-n-pyridyl-n-furyl(od r thienyl)-methyl-propylamine, ihre herstellung und diese enthaltende pharmazeutische mittel.
ATE160567T1 (de) Psoralen-derivate, deren herstellung und verwendung als arzneimittel
DE69412794D1 (de) 2'-desoxy-5-fluoruridin, pharmazeutisch anwendbare salze davon, verfahren zu ihrer herstellung und antitumormedikament
ATE77362T1 (de) Naphthalenische antipsoriasismittel und ihr herstellungsverfahren.
ATE56440T1 (de) 6-oxo-pyridazinyl-verbindungen.
ATE83484T1 (de) 20,21-dinoreburnamenin-derivate, substituiert in position 15 durch eine aminogruppe und deren salze, verfahren zu deren herstellung und die auf diese weise erhaltenen zwischenverbindungen, deren anwendung als arzneimittel und diese enthaltende pharmazeutische zusammensetzungen.